Category: Peptide Science
-
How does Semax cross the BBB despite being a heptapeptide, and what does its actual brain pharmacokinetic curve look like when delivered intranasally vs. subcutaneously?
Semax reaches the brain rapidly after either SC or IN administration because its small, polar, metabolically stable structure allows low-efflux passive
-
If the most-cited BPC-157 healing effects come almost entirely from one lab’s rodent studies, what does that imply about the actual evidence base behind the most popular biohacker peptide on the market?
The healing mystique of BPC-157 is built on one prolific Croatian lab’s unreplicated rodent studies, making the peptide the most widely self-experimente
-
Most practitioners assume oral BPC-157 survives gastric transit because Sikiric’s papers say so — but if the pharmacokinetic studies used to prove this have never been independently replicated in humans, are oral protocols just placebo with extra steps?
Oral BPC-157 protocols hinge on a single un-replicated in-vitro gastric-juice study plus rodent lesion data that cannot distinguish local mucosal action
-
If GHK-Cu’s transcriptomic effects (“regulates 4,000 genes”) were obtained at supraphysiological concentrations in vitro, what fraction of marketed topical creams could plausibly reproduce any of them on intact human skin?
Fewer than one in twenty commercially marketed GHK-Cu creams can reach the micromolar epidermal concentrations required to replicate the famous 4,000-ge
-
What if the apparent efficacy of “peptide stacks” is mostly an artifact of confounded protocols (concurrent TRT, diet, sleep optimization, training changes) rather than the peptides themselves?
Every source that enthusiastically reports peptide benefits simultaneously manipulates sleep, diet, training, and hormonal milieu, while the only contro
-
If retatrutide’s weight loss curve is steeper than tirzepatide’s mostly because of glucagon-driven energy expenditure, does that mean the true comparator isn’t another GLP-1 — it’s DNP, and we should be asking the same safety questions?
Retatrutide’s glucagon-driven energy expenditure makes DNP—not tirzepatide—the correct mechanistic benchmark, so the safety questions that once buried D
-
Why does the longevity community treat Khavinson’s bioregulator data as foundational when essentially none of the key lifespan-extension claims have been replicated outside the St. Petersburg institute?
Khavinson’s peptides remain the longevity world’s favorite “Russian dolls”—beautifully nested story layers that no one outside St. Petersburg has been w
-
If Tesamorelin only modestly reduces visceral adipose tissue (~15%) in its approved HIV-lipodystrophy population, why do off-label users expect dramatic body recomposition — and what cognitive bias is doing the lifting?
Off-label tesamorelin hype is powered by the availability cascade that substitutes the dramatic 20 % fat-loss figure from true GH studies for the peptid
-
Could the entire “peptides are safer than steroids” framing be a category error, given that we have decades of human safety data on AAS and essentially none on most performance peptides?
The claim that peptides are safer than steroids is a category error because it pits a well-characterized, decades-old risk curve (AAS) against an almost
-
Is Semax’s nootropic reputation in the West a translation artifact — Russian clinical practice uses it almost exclusively for stroke recovery, not cognitive enhancement in healthy adults?
Semax’s Western nootropic halo is a selective reinterpretation; in its homeland it remains a short-course stroke-recovery drug with no published evidenc